Dr Michael Raymont, chief executive of Albert Labs, spoke to Proactive about the toxicology research for KRN-101.
KRN-101 is a psilocybin-based drug, and is used as a treatment for cancer-related anxiety.
Dr Raymont said the company is getting ready to trial this in the Autumn, and investors should know it is making steady progress.